UCLA Integrated Staging System (UISS) for Renal Cell Carcinoma (RCC)
Provides 5-year disease-free prognosis for localized and metastatic RCC.
- Localized: Any T; N0; M0
- Metastatic: T>0; N>1; M>1
Advice
The UISS score is often used for screening and stratifying patients into modern therapy trials, including trials of VEGF therapy such as sunitinib. The consistency of results in validation studies is somewhat reassuring, and one advantage is its applicability to patients with and without metastatic disease.
Management
We are unaware of validated management algorithms using the score.
Critical Actions
The UISS score is complex, requiring close attention to multiple variables for correct classification.